The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARa) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Exelixis; Genentech/Roche; Incyte; Lantheus Medical Imaging
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to therapeutic cancer vaccines, managed by Johns Hopkins
(OPTIONAL) Uncompensated Relationships - Merck
 
Stephen Chan
Honoraria - AstraZeneca; Eisai; Elevar Therapeutics; Ipsen; MSD (Inst); Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Exelixis; MSD Oncology; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Roche
 
Julien Edeline
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Guerbet; Incyte; Ipsen; Jazz Pharmaceuticals; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology
Research Funding - AstraZeneca (Inst); Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences; Summit Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Coherus Biosciences; Eisai; Exelixis; Genentech; Jazz Pharmaceuticals; Merck; Merus; Sumitomo Pharma Oncology; TransThera Biosciences; TriSalus Life Sciences
Research Funding - AstraZeneca (Inst)
 
Darrin Bomba
Employment - CytomX Therapeutics; Kezar Life Sciences; Quanta Therapeutics (I); Tempest Therapeutics
Stock and Other Ownership Interests - Kezar Life Sciences; Tempest Therapeutics
 
Yonchu Jenkins
Employment - Abalone Biosciences (I); Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson/Janssen (I); Novartis (I); Seagen (I); Vertex (I)
Consulting or Advisory Role - Xoma (I)
 
Steven Smith
Consulting or Advisory Role - AtlasMedx; Kirilys Therapeutics; Mineralys Therapeutics; Syndax; Tempest Therapeutics; Treeline Biosciences
 
Nathan Standifer
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Amgen; AstraZeneca; Tempest Therapeutics
Consulting or Advisory Role - Vincerx Pharma
Patents, Royalties, Other Intellectual Property - TRIAZOLONE COMPOUNDS AND USES THEREOF; USES OF EP2/EP4 ANTAGONIST COMPOUNDS
 
Arndt Vogel
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Sam Whiting
Employment - Recludix Pharma (I); Tempest Therapeutics
Leadership - Recludix Pharma (I); Tempest Therapeutics
Stock and Other Ownership Interests - Recludix Pharma (I); Tempest Therapeutics
Consulting or Advisory Role - Boundless Bio (I); Caribou Biosciences (I)